We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.30
Bid: 19.00
Ask: 19.96
Change: -0.20 (-1.03%)
Spread: 0.96 (5.053%)
Open: 20.00
High: 20.00
Low: 18.66
Prev. Close: 19.50
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Liability Waived

31 Jul 2019 07:00

RNS Number : 2836H
Nanoco Group PLC
31 July 2019
 

31 July 2019

NANOCO GROUP PLC

("Nanoco", the "Company" or the "Group")

 

Contract Liability Waived

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, today announces an update to the current contract with the US Customer.

The US Customer has formally released Nanoco from its obligation to repay £4.25m of capital funding provided for the new Runcorn production facility due to the uncertainty over the timing or use of the facility to manufacture the new nanomaterials. The facility was completed in December 2018 and is currently undergoing commissioning as part of the current contract of work that is due to expire on 31 December 2019.

While still subject to external audit, the lack of contracted production orders on the new Runcorn facility, means that an accounting impairment charge is likely to be made in the year end accounts. Immediately prior to any such impairment, the net book value of the new facility is forecast to be approximately £3.7m. The difference in the two values above reflects depreciation already charged in the year. In addition to both items above, approximately £0.5m of other contract specific raw materials and minor contractual liabilities are also likely to require provisioning at the end of the current financial year. None of the above accounting items have any impact on cash.

For the avoidance of doubt, the operational capability and capacity of the plant has in no way been impaired. Commissioning work continues in line with the current contract with the US Customer. Once that contract is complete in December 2019, the full production capacity will remain available for use by Nanoco to service any future demand from the US Customer or any other potential new customers with whom the Group is in early stage discussions.

As previously announced, the Group still expects to deliver a cash breakeven positon for the twelve months ending December 2019 and to have £6.0m of cash on hand at that time.

Michael Edelman, Chief Executive of Nanoco, said:

"The waiver of the contract liability and the impairment of the Runcorn plant creates a balanced outcome for Nanoco. While the impairment of the plant reflects the lack of current commercial contracts - the plant remains at our disposal and fully capable of producing high quality nanomaterials for use in a number of electronics applications.

With the validation of production material nearing completion, the time to market will be significantly reduced when new commercial customers are identified and we continue our efforts in this area to identify new potential opportunities and to provide excellent service to the US Customer."

This announcement contains inside information as defined in EU Regulation No. 596/2014 and is in accordance with the Group's obligations under Article 17 of that Regulation.

 

The person responsible for arranging for the release of this announcement on behalf of the Group is Brian Tenner, Chief Operating Officer and Chief Financial Officer.

 

For further information, please contact:

Nanoco Group PLC

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

Brian Tenner, Chief Financial Officer

Caroline Watson, Investor Relations Manager

Tel: + 44 (0) 7799 897357

cwatson@nanocotechnologies.com

 

MHP Communications

Tel: +44 (0) 20 3128 8570

Reg Hoare / Giles Robinson / Pete Lambie

nanoco@mhpc.com

 

Notes for editors:

 

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display and Electronics markets. One of the interesting properties of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company, Merck KGaA of Germany and Wah Hong Industrial Corporation of Taiwan.

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CNTUROURKWABOUR
Date   Source Headline
13th Jul 202212:00 pmRNSDirector/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
30th Jun 20227:00 amRNSTotal Voting Rights
29th Jun 20227:00 amRNSChange of Auditor
23rd Jun 20223:48 pmRNSDirector/PDMR Shareholding
22nd Jun 20222:25 pmRNSHolding(s) in Company
21st Jun 20223:36 pmRNSDirector/PDMR Shareholding
21st Jun 20229:06 amRNSReplacement: Director/PDMR Shareholding
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
17th Jun 20224:36 pmRNSPrice Monitoring Extension
17th Jun 202210:45 amRNSHolding(s) in Company
14th Jun 20229:42 amRNSHolding(s) in Company
9th Jun 20227:00 amRNSBlock listing Six-monthly Return
8th Jun 202212:00 pmRNSResults of Fundraise
8th Jun 20227:00 amRNSFundraise significantly over-subscribed
7th Jun 20225:16 pmRNSReplacement: Litigation Update
7th Jun 20224:55 pmRNSLitigation Update
6th Jun 20227:02 amRNSTrading Update & Proposed Fundraise
6th Jun 20227:00 amRNSMajor Work Package for European Customer
23rd May 20225:00 pmRNSHolding(s) in Company
17th May 20227:02 amRNSLitigation Update
13th May 202212:15 pmRNSHolding(s) in Company
13th Apr 20222:49 pmRNSHolding(s) in Company
12th Apr 20227:00 amRNSInterim Results
17th Mar 20227:00 amRNSAdditional Work Package for European Customer
15th Mar 20227:00 amRNSNotice of Interim Results
4th Feb 20223:14 pmRNSHolding(s) in Company
31st Jan 20227:00 amRNSTotal Voting Rights
9th Dec 20217:00 amRNSBlock listing Six-Monthly Return
2nd Dec 20217:18 amRNSBlock Listing Application
1st Dec 202112:30 pmRNSDirector/PDMR Shareholding
1st Dec 202112:28 pmRNSAnnual General Meeting – Voting Results
30th Nov 20217:00 amRNSAGM Statement
18th Nov 20211:13 pmRNSDirector/PDMR Shareholding
9th Nov 20217:11 amRNSDirector/PDMR Shareholding
8th Nov 20217:00 amRNSDirector Appointment
5th Nov 202111:25 amRNSAdditional Work Package for European Customer
4th Nov 20216:20 pmRNSNotice of AGM
3rd Nov 20217:00 amRNSPreliminary Results
18th Oct 20216:10 pmRNSChange to final results announcement date
13th Oct 20219:30 amRNSPresentation via Investor Meet Company
8th Oct 20211:48 pmRNSNotice of Results
19th Aug 20217:00 amRNSNon-Executive Director Appointment
16th Jul 20214:41 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
15th Jul 20217:00 amRNSNon-dilutive loan note subscription
5th Jul 20217:30 amRNSDevelopment Agreement
28th Jun 20217:00 amRNSLitigation update and non-dilutive debt facility
10th Jun 202111:33 amRNSBlocklisting Six-Monthly Return
24th May 202112:20 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.